This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Treatment of pneumococcal pneumonia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Pneumococcal pneumonia is generally treated with amoxycillin, doxycycline or clarithromycin. (1)

For severe infections:

  • intravenous antibiotics e.g. amoxicillin, doxycycline. Oral treatment can be used when the pneumonia is resolving clinically and the patient is apyrexial.

For mild-moderate infections:

  • amoxicillin 500mg-1g tds for 10-14 days* PO (1)
    • in patients allergic to penicillin, a suitable alternative is erythromycin 500mg qds PO or clarithromycin 500mg bd** PO (1)

Alternative treatments in penicillin allergy include erythromycin or cefuroxime (but note 10% cross-sensitivity).

Prophylaxis:

  • pneumococcal vaccination

Notes:

  • *BTS guidelines recommend adequate dosing of amoxicillin to cover intermediate-resistant strains of Strep pneumoniae
  • ** clarithromycin may be substituted for those with gastrointestinal intolerance to oral erythromycin and also has benefit of twice daily dosage

Reference:

Pneumonia (community-acquired): antimicrobial prescribing. NICE guideline [NG138]Published: 16 September 2019

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.